Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.The published data showed that fol ...

Note: I previously covered Ardmore Shipping (NYSE: ASC ) in October. In my last note, I discussed the company’s fleet, product tanker market, and financials. I was not excited about average dividends and a lack of buybacks. At that time, Ardmore traded at 73% PNAV. Despite the discountI am a voracious reader and self-taught investor. In the past, I was an accountant in the maritime industry. Now, I am a happy retiree passionate about writing and financial markets. As the kids are grown up, I have time to pu ...

公司基本情况 - Ardmore Shipping Corporation是一家市值5亿美元的海运公司主要运输化学品和石油产品拥有26艘船其中包括4艘租入船载重吨位在25000到50000之间[1] 分析师情况 - 分析师专注于个股分析有金融和经济学教育背景关注股市趋势投资理念注重简单性通过Seeking Alpha平台与全球投资者交流且未持有提及公司股票无相关计划且文章表达自己观点未接受除Seeking Alpha之外的报酬与提及公司无商业关系[2][3] 平台情况 - Seeking Alpha平台过去表现不保证未来结果不提供投资建议分析师为第三方作者包括专业和个人投资者且平台不是持牌证券商经纪人或投资顾问或投资银行[4]

-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.This Phase III clinical trial is a randomized, double-blind, pla ...

公司ASC47临床研究相关 - ASC47在澳大利亚针对低密度脂蛋白胆固醇（LDL - C）升高受试者的I期单剂量递增（SAD）研究数据显示 皮下（SQ）注射的ASC47半衰期为21天 支持肥胖患者每月给药一次[1] - ASC47在多项临床前研究中展示出健康的减肥效果（保留肌肉的减肥）[1] - 在与司美格鲁肽的临床前头对头研究中 ASC47减少总脂肪量（-63.5%）显著多于司美格鲁肽（-39.6%）ASC47增加总肌肉量（+5.8%）司美格鲁肽减少总肌肉量（-9.3%）二者总体重减少相似 但ASC47治疗的饮食诱导肥胖（DIO）小鼠热量摄入减少显著少于司美格鲁肽治疗的DIO小鼠[1] - 在与替尔泊肽的临床前头对头研究中 ASC47减少总脂肪量（-68.0%）显著多于替尔泊肽（-50.4%）ASC47增加总肌肉量（+8.1%）替尔泊肽减少总肌肉量（-3.8%）二者总体重减少相似 但ASC47治疗的DIO小鼠热量摄入减少显著少于替尔泊肽治疗的DIO小鼠[1] - ASC47设计独特 能靶向递送至脂肪组织 使脂肪组织中药物浓度呈剂量依赖性升高 在DIO小鼠中 15mg/kg SQ给药 每两周一次 最后一次给药14天后 脂肪组织中的药物浓度是临床前模型预测的人类有效药物浓度的7倍[1] - ASC47减少脂肪和实现保留肌肉减肥的关键作用机制之一是通过脂肪组织中解偶联蛋白1（UCP - 1）介导的产热[1][13] - ASC47单药治疗在LDL - C升高受试者中的SAD研究有五个队列 受试者分别接受10mg、30mg、90mg、180mg、360mg ASC47或安慰剂 前三个队列（10mg、30mg和90mg）已完成给药 共20名LDL - C升高的受试者接受了ASC47或安慰剂 ASC47耐受性良好 无严重不良事件（SAE）无因不良事件（AE）停药 多数AE为轻度（1级）仅2名受试者（2/20）报告轻度注射部位反应（仅1级）无胃肠道和心脏AE报告 无异常肝酶报告 实验室检查、心电图、生命体征或体格检查无有临床意义的发现[3] - 基于ASC47单药治疗LDL - C升高受试者的SAD研究的安全性、药代动力学和靶点结合数据 在澳大利亚启动了第二项I期研究（肥胖患者中ASC47单药治疗的SAD研究）预计2025年第一季度获得初步数据[4] - ASC47在澳大利亚还有两项I期研究：肥胖患者中ASC47单药治疗的多剂量递增（MAD）研究 以及肥胖患者中ASC47与替尔泊肽或司美格鲁肽联合的MAD研究 预计2025年在医学会议上展示详细临床数据[5] 公司Ascletis相关 - Ascletis是一家在香港证券交易所（1672.HK）上市的创新研发驱动的生物技术公司 涵盖从发现和开发到GMP制造的整个价值链 由具有深厚专业知识和良好业绩的管理团队领导 专注于代谢疾病和病毒性疾病两个全球未满足医疗需求的治疗领域 其研发管线中有多个临床阶段的候选药物[18]

财务数据和关键指标变化 - 公司在2024年第三季度报告的调整后收益为2330万美元，每股收益为0.55美元，反映出TCE（时间加权平均运费）率高于历史水平 [6][24] - MRs（中型油轮）在第三季度的日均收益为28500美元，第四季度至今为25000美元，已预定50% [6] - 化学油轮在第三季度的日均收益为21600美元，第四季度至今为25150美元，已预定55% [6] - 公司将现金盈亏平衡水平降低至11500美元/天，为历史最低水平，提供了灵活性和韧性 [9][23] 各条业务线数据和关键指标变化 - MRs和化学油轮的TCE率在第三季度同比上升，且年初至今增长了17% [7][30] - 公司在2024年完成了所有计划的干船坞，确保全舰队在冬季市场开始时处于最佳状态 [25] 各个市场数据和关键指标变化 - 市场前景乐观，预计进入季节性强劲的冬季市场，受炼油厂运行增加、天气延误和整体交易活动提升的驱动 [10][30] - 全球MR船队的老龄化问题显著，预计未来五年内50%的全球MR船队将超过20年并进入拆解窗口 [18][22] 公司战略和发展方向和行业竞争 - 公司继续专注于优化交易表现，同时严格控制成本，致力于在高利率环境中减少债务 [15][23] - 公司在投资舰队方面采取高回报策略，计划在2025年进行约3000万至3500万美元的资本支出，涵盖常规干船坞和高回报性能升级 [26] 管理层对经营环境和未来前景的评论 - 管理层认为市场基本面依然强劲，尽管短期内存在波动，长期需求驱动因素仍然支持市场 [30] - 由于地缘政治冲突和新规的影响，市场交易复杂性增加，为公司提供了更多机会 [21] 其他重要信息 - 公司已连续第八次宣告分红，累计分红相当于市场资本的15% [14] - 公司在2024年投资了1500万美元用于提高效率的技术和洗涤器安装，已提升强劲的租船表现 [25] 问答环节所有提问和回答 问题: 关于特朗普胜选对产品市场的影响 - 管理层表示市场基本面依然积极，不会受到美国总统选举的影响，供应和需求动态保持稳定 [34][35] 问题: 关于第四季度的预定情况 - 管理层确认目前的预定情况高于市场指数，反映出公司在最大化TCE表现方面的成功 [38] 问题: 关于资产定价和购买决策 - 管理层强调在资产购买方面将保持谨慎，确保任何投资决策符合价值标准 [42][43] 问题: 关于优先股回购的看法 - 管理层表示优先股和债务的减少是整体债务减少策略的一部分，未来将继续评估市场情况 [48][49]

Ardmore Shipping (ASC) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.77%. A quarter ago, it was expected that this shipping company would post earnings of $1.08 per share when it actually produced earnings of $1.13, delivering a surprise of 4.63%.Over the last four quarters, the c ...

HAMILTON, Bermuda, Nov. 6, 2024 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2024.Highlights and Recent Activity Reported net income and Adjusted earnings of $23.3 million for the three months ended September 30, 2024, or $0.55 earnings and Adjusted earnings per basic share and diluted share, compared to net income attributable to common stockholders and Adjusted earnings of $20.3 million ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Ardmore Shipping (ASC) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nove ...

HAMILTON, Bermuda, Oct. 23, 2024 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that the Company plans to announce its third quarter earnings before the market opens Wednesday, November 6, 2024 and will host a conference call later in the day at 10:00 a.m. Eastern Time. The conference call and slide presentation will also be broadcast live over the Internet.Conference Call and Webcast Details:Wednesday, November 6, 2024, at 10:00 a.m. Eastern TimeLive w ...